A 6-month Efficacy, Safety and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Must sign an Informed Consent Form
In remission from past hepatic encephalopathy (HE).
Appropriate birth control measures
More than or equal to 18 years of age.
Must be potential for benefit from treatment.
Recent prior HE episodes
Capable and willing to comply with all study procedures.
Subject has personal support available
Has a certain Model End Stage Liver Disease (MELD) score
Recent TIPS placement or revision
Significant medical conditions, medical conditions that may impact study participation, or Investigator decision not to include.
Allergies to the study drug or similar drugs.
Recent participation in another clinical trial
History of non-compliance
Pregnant or at risk of pregnancy, or is lactating.
Recent alcohol consumption
Active bacterial or viral Infections
On a prohibited medication.
Liver transplant expected in near term
Subject shows presence of intestinal obstruction or has inflammatory bowel disease.